We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IRIS V-Study: Pioglitazone Reduces High-Sensitivity CRP Values in Patients with Type 2 Diabetes Under Daily Routine Conditions.
- Authors
Pfützner, Andreas; Schöndorf, Thomas; Lübben, Georg; Flannery, Manja; Grabellus, Martin; Roth, Werner; Forst, Thomas; Karagiannis, Efstrathios
- Abstract
Type 2 diabetes mellitus is associated with several cardiovascular risk factors including postprandial glucotoxicity and a chronic vascular inflammation. With respect to the latent inflammation, the most reliable and accessible marker currently available for clinical use is high-sensitive C-reactive protein (hsCRP). This observational trial was performed to evaluate the effect of pioglitazone treatment on hsCRP levels in a large population under daily life conditions. The observational study was performed in Germany and 1167 with complete data sets could be included into the final analyses (536 women: age (mean±SD): 65±10 years, disease duration 6.8±6.8 years, BMI: 31.8±6.8 kg/m²; 631 men: age: 63±10 years, disease duration 7.2±9.8 years, BMI: 30.6±5.1 kg/m²). 1007 patients (471 female, 533 male) suffered from hypertension (RR> 140/90 mmHg and/or antihypertensive medication). The patients received additional pioglitazone (30 mg/day or 45 mg/day) in combination with their previous treatment with sulfonylurea and/or metformin and were evaluated at baseline and after 20±2 weeks. HsCRP values were determined at baseline and endpoint by solid-phase enzyme immunoassay and subsequent colorimetric quantification in a central lab. At baseline, the mean hsCRP levels of the entire population indicated a high cardiovascular risk (5.2±4-11.1 mg/l). A significant improvement could be observed at endpoint for hsCRP with a decline by 14% in the whole group independent from the other concomitant treatments. This effect was observed for both the female (hsCRP decline by 11%) and the male subgroup (hsCRP decline by 16%, p<0.05 in both cases). These observational results, obtained from a non-selected patient population under routine clinical conditions, confirm the beneficial effects of pioglitazone on the chronic inflammation of the vasculature as seen in smaller controlled comparator studies.
- Subjects
HYPOGLYCEMIC agents; C-reactive protein; PEOPLE with diabetes; TYPE 2 diabetes; INFLAMMATION; HYPERTENSION
- Publication
Diabetes, 2007, Vol 56, pA586
- ISSN
0012-1797
- Publication type
Article